ColoNext – pro
ColoNext is a guideline-based, disease-specific test option that includes up to 26 genes associated with hereditary colorectal and gastric cancer and polyposis. Genetic testing for colon cancer is recommended for individuals with a family history or personal risk factors for developing the disease. National Comprehensive Cancer Network (NCCN) has announced new guidelines that recommend germline multigene panel testing for all individuals with CRC ages <50, as well as consideration for germline multigene panel testing for those with evidence of mismatch repair deficiency in their tumor or a family history of CRC.
Cragun D, Radford C, Dolinsky JS, Caldwell M, Chao E, Pal T. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet. 2014 Dec;86(6):510-20. doi: 10.1111/cge.12359. Epub 2014 Mar 20. PMID: 24506336; PMCID: PMC4127163.
Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. JAMA Oncol. 2021;7(2):230–237. doi:10.1001/jamaoncol.2020.6252
NCCN Colon Cancer 2025